Epidemiologic and Genetic Study on Familial Prostate Cancer

Key facts

Sponsor

Centre de Recherche sur les Pathologies Prostatiques

Principal Investigator

Olivier Cussenot, MD, Ph.D.

Centre de Recherche sur les Pathologies Prostatiques

Enrollment

10000 target

Eligibility

18 years · All sexes

Timeline

1996 – 2026

Study locations (5)

• Department of Urology, CHU Angers, Angers, France
• Department of Urology, Hopital de la Cavale Blanche, Brest, France
• Department of Urology, CHU Dijon, Dijon, France
• Department of Urology, Hopital Pitié-Salpetriere, Paris, France
• Department of Urology, Hopital Tenon, Paris, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Familial prostate cancer

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNANCT06470685
  Prophylactic Prostatectomy for Prostate Cancer (PPPC)
  Royal Marsden NHS Foundation Trust
• RECRUITINGNCT06433349
  A Multi-center Investigation of Family Health.
  Odense University Hospital
• RECRUITINGNANCT06171139
  Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
  University of California, San Francisco
• ACTIVE NOT RECRUITINGNANCT04763915
  Improving Care After Inherited Cancer Testing
  Vanderbilt-Ingram Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT04090528
  pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
  University of Wisconsin, Madison
• ACTIVE NOT RECRUITINGPHASE2NCT03725761
  Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
  University of Wisconsin, Madison

See all trials for Familial prostate cancer →